1. |
Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin, 2016, 66(2): 115-132.
|
2. |
Siegel RL, Miller KD, Jemal A. Cancer statistics, 2017. CA Cancer J Clin, 2017, 67(1): 7-30.
|
3. |
Waqar S, Khan SA, Sarfraz T, et al. Expression of estrogen receptors (ER), progesterone receptors (PR) and HER-2/neu receptors in endometrial carcinoma and their associations with histological types, grades and stages of the tumor. Pak J Med Sci, 2018, 34(2): 266-271.
|
4. |
张岩, 廖秦平, 于丽, 等. 子宫内膜癌细胞雌激素受体亚型的调控和功能的初步研究. 中华妇产科杂志, 2005, 40(8): 558-561.
|
5. |
王志启, 王建六, 魏丽惠, 等. 子宫内膜癌细胞中细胞膜雌激素受体表达的初步研究. 中华妇产科杂志, 2006, 41(7): 471-475.
|
6. |
Su T, Qu JJ, Wang K, et al. Cross-talk between p21-activated kinase 4 and ER alpha signaling triggers endometrial cancer cell proliferation. Oncotarget, 2017, 8(40): 68083-68094.
|
7. |
牛艺洁, 史惠蓉, 谢娅. 二甲双胍对孕激素耐药的子宫内膜癌细胞的调节作用. 中华妇产科杂志, 2016, 51(2): 135-140.
|
8. |
Zhang JB, Xu H, Zhou XE, et al. Role of metformin in inhibiting estrogen-induced proliferation and regulating ER alpha and ER beta expression in human endometrial cancer cells. Oncol Lett, 2017, 14(4): 4949-4956.
|
9. |
Tian WY, Teng F, Zhao J, et al. Estrogen and insulin synergistically promote type 1 endometrial cancer progression. Cancer Biol Ther, 2017, 18(12): 1000-1010.
|
10. |
Rizner TL. Estrogen biosynthesis, phase I and phase II metabolism, and action in endometrial cancer. Mol Cell Endocrinol, 2013, 381(1/2): 124-139.
|
11. |
Hapangama DK, Kamal AM, Bulmer JN. Estrogen receptor beta: the Guardian of the endometrium. Hum Reprod Update, 2015, 21(2): 174-193.
|
12. |
Thomas C, Gustafsson JÅ. The different roles of ER subtypes in cancer biology and therapy. Nat Rev Cancer, 2011, 11(8): 597-608.
|
13. |
Li JP, Zhuang QR, Lan XP, et al. PES1 differentially regulates the expression of ER alpha and ER beta in ovarian cancer. IUBMB Life, 2013, 65(12): 1017-1025.
|
14. |
Bardin A, Boulle N, Lazennec G, et al. Loss of ER beta expression as a common step in estrogen-dependent tumor progression. Endocr Relat Cancer, 2004, 11(3): 537-551.
|
15. |
Ahlin C, Lundgren C, Embretsen-Varro E, et al. High expression of cyclin D1 is associated to high proliferation rate and increased risk of mortality in women with ER-positive but not in ER-negative breast cancers. Breast Cancer Res Treat, 2017, 164(3): 667-678.
|
16. |
Ye D, Luo H, Lai ZY, et al. ClC-3 chloride Channel proteins regulate the cell cycle by up-regulating cyclin D1-CDK4/6 through suppressing p21/p27 expression in nasopharyngeal carcinoma cells. Sci Rep, 2016, 6: 30276.
|
17. |
Mahabaleshwarkar R, Liu TL, Mulder H. Comparative effectiveness of metformin dosage uptitration versus adding another antihyperglycemic medication on glycemic control in type 2 diabetes patients failing initial metformin monotherapy: a retrospective cohort study. Popul Health Manag, 2019.
|
18. |
Pernicova I, Korbonits M. Metformin--mode of action and clinical implications for diabetes and cancer. Nat Rev Endocrinol, 2014, 10(3): 143-156.
|
19. |
Hopkins BD, Pauli C, Xing D, et al. Suppression of insulin feedback enhances the efficacy of PI3K inhibitors. Nature, 2018, 560(7719): 499.
|
20. |
Eikawa S, Nishida M, Mizukami S, et al. Immune-mediated antitumor effect by type 2 diabetes drug, metformin. Proc Natl Acad Sci USA, 2015, 112(6): 1809-1814.
|
21. |
Cantrell LA, Zhou C, Mendivil A, et al. Metformin is a potent inhibitor of endometrial cancer cell proliferation--implications for a novel treatment strategy. Gynecol Oncol, 2010, 116(1): 92-98.
|